SiREX-Stent for the Treatment of SymptOmatic Lateral VEnous Sinus Stenosis

Inclusion Criteria: * • Patient ≥ 18 years old * Disabling pulsatile tinnitus lasting for more than three months * Venous type: pulsatile tinnitus is interrupted by ipsilateral jugular vein compression * Lateral sinus stenosis visible on venous MRA or venous angio CT * Exclusion of other cause (excepted dehiscence of the lateral sinus related to the stenosis) of PT on MRI and on the temporal bone CT * Stenosis located on a dominant or codominant lateral sinus * Stenosis associated with a venous gradient of at least 3 mm Hg under general anesthesia (GA) in the absence of sinus dehiscence, or 2 mm Hg under GA if there is sinus dehiscence in a mastoid cell * Patients asking for the treatment of her/his pulsatile tinnitus * Patients accepting to receive the SiREX® Stent (instead of a carotid stent) * Written informed consent Exclusion Criteria: * Non-pulsatile tinnitus or pulsatile tinnitus unrelated to lateral sinus stenosis * Stenosis with gradient \< 2 mm Hg in the absence of associated lateral sinus dehiscence * Any contraindication for treatment according to Instructions for Use: * Patients in whom the size of the venous vessel section to be treated does not lie within the range indicated for the stent. * Patients for whom angiography shows that the anatomic morphology is not suitable for endovascular treatment due to severe vessel tortuosity or stenosis.Patients who were not pre-treated with antiplatelet agents prior to the procedure. * Patients in whom treatment with antiplatelet agents and/or anticoagulants is contraindicated. * Patients with an acute subarachnoid haemorrhage. * Patients with an active bacterial infection. * Patients who are hypersensitive to nickel-titanium. * Pregnant or breastfeeding woman * Subject is participating in another clinical study * Patients with a life-threatening event in the last 6 months * Patients with a life expectancy under 12 months * Known, severe comorbidities, which will likely influence carrying out of the follow-up visits (cancer, alcohol/drug abuse or dementia)